Logo image of HCWB

HCW BIOLOGICS INC (HCWB) Stock Fundamental Analysis

NASDAQ:HCWB - Nasdaq - US40423R1059 - Common Stock - Currency: USD

7.77  +0.72 (+10.21%)

Fundamental Rating

1

Taking everything into account, HCWB scores 1 out of 10 in our fundamental rating. HCWB was compared to 568 industry peers in the Biotechnology industry. HCWB may be in some trouble as it scores bad on both profitability and health. HCWB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

HCWB had negative earnings in the past year.
In the past year HCWB has reported a negative cash flow from operations.
In the past 5 years HCWB always reported negative net income.
HCWB had a negative operating cash flow in each of the past 5 years.
HCWB Yearly Net Income VS EBIT VS OCF VS FCFHCWB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of HCWB (-99.30%) is worse than 75.70% of its industry peers.
Industry RankSector Rank
ROA -99.3%
ROE N/A
ROIC N/A
ROA(3y)-72.93%
ROA(5y)-57.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HCWB Yearly ROA, ROE, ROICHCWB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Gross Margin of HCWB (37.38%) is better than 74.47% of its industry peers.
The Profit Margin and Operating Margin are not available for HCWB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HCWB Yearly Profit, Operating, Gross MarginsHCWB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

HCWB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HCWB has been increased compared to 1 year ago.
The number of shares outstanding for HCWB has been increased compared to 5 years ago.
HCWB has a worse debt/assets ratio than last year.
HCWB Yearly Shares OutstandingHCWB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HCWB Yearly Total Debt VS Total AssetsHCWB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

HCWB has an Altman-Z score of -8.54. This is a bad value and indicates that HCWB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of HCWB (-8.54) is worse than 70.25% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.54
ROIC/WACCN/A
WACC9.63%
HCWB Yearly LT Debt VS Equity VS FCFHCWB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.19 indicates that HCWB may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.19, HCWB is doing worse than 96.30% of the companies in the same industry.
A Quick Ratio of 0.19 indicates that HCWB may have some problems paying its short term obligations.
HCWB's Quick ratio of 0.19 is on the low side compared to the rest of the industry. HCWB is outperformed by 96.30% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
HCWB Yearly Current Assets VS Current LiabilitesHCWB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

HCWB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -66.67%.
HCWB shows a decrease in Revenue. In the last year, the revenue decreased by -9.53%.
HCWB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.50% yearly.
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-966.67%
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y-11.5%
Revenue growth 5YN/A
Sales Q2Q%-70.17%

3.2 Future

Based on estimates for the next years, HCWB will show a very negative growth in Earnings Per Share. The EPS will decrease by -142.16% on average per year.
HCWB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 141.38% yearly.
EPS Next Y-3222.29%
EPS Next 2Y-466.19%
EPS Next 3Y-215.73%
EPS Next 5Y-142.16%
Revenue Next Year368.22%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y141.38%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HCWB Yearly Revenue VS EstimatesHCWB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2028 2029 2030 200M 400M 600M
HCWB Yearly EPS VS EstimatesHCWB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HCWB. In the last year negative earnings were reported.
Also next year HCWB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HCWB Price Earnings VS Forward Price EarningsHCWB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCWB Per share dataHCWB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

HCWB's earnings are expected to decrease with -215.73% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-466.19%
EPS Next 3Y-215.73%

More info and screens

0

5. Dividend

5.1 Amount

HCWB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HCW BIOLOGICS INC

NASDAQ:HCWB (4/21/2025, 8:19:15 PM)

7.77

+0.72 (+10.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/dmh
Earnings (Next)N/A N/A
Inst Owners7.02%
Inst Owner Change0%
Ins Owners40.57%
Ins Owner Change0%
Market Cap8.70M
Analysts82.86
Price TargetN/A
Short Float %2.21%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3900%
EPS NY rev (3m)-3900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.39
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-22.44
Fwd EYN/A
FCF(TTM)-12.94
FCFYN/A
OCF(TTM)-12.7
OCFYN/A
SpS2.29
BVpS-6.04
TBVpS-6.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.38%
FCFM N/A
ROA(3y)-72.93%
ROA(5y)-57.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.09%
Cap/Sales 10.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -8.54
F-Score2
WACC9.63%
ROIC/WACCN/A
Cap/Depr(3y)665.42%
Cap/Depr(5y)407.44%
Cap/Sales(3y)127.14%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-966.67%
EPS Next Y-3222.29%
EPS Next 2Y-466.19%
EPS Next 3Y-215.73%
EPS Next 5Y-142.16%
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y-11.5%
Revenue growth 5YN/A
Sales Q2Q%-70.17%
Revenue Next Year368.22%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y141.38%
EBIT growth 1Y-12.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.81%
OCF growth 3YN/A
OCF growth 5YN/A